TY - JOUR
T1 - Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor
T2 - a contemporary single-institution review
AU - Bruzoni, Matias
AU - Parikh, Purvi
AU - Celis, Rolando
AU - Are, Chandrakanth
AU - Ly, Quan P.
AU - Meza, Jane L.
AU - Sasson, Aaron R.
PY - 2009/3
Y1 - 2009/3
N2 - Background: Pancreatic nonfunctioning neuroendocrine tumors (PNFNETs) are an uncommon malignancy and often present with metastatic disease. There is a lack of information on the management of the primary tumor in patients who present with unresectable synchronous hepatic metastases. Methods: A retrospective review (2001-2008) of PNFNETs was conducted. Patients were divided into 3 groups: PNFNET without evidence of hepatic metastasis (group A), PNFNET with metastatic disease involving less than 50% of the liver (group B), and PNFNET with metastatic disease involving more than 50% of the liver (group C). Clinical data and outcomes were analyzed. Results: Thirty-five patients with PNFNET were identified (group A = 15, group B = 11, group C = 9). Resection of the pancreatic tumor was performed in 26 patients. With a mean follow-up period of 30 months, death from disease progression occurred in 1 patient in group A, none in group B, and in 7 in group C. Conclusions: In selected patients, resection of the primary pancreatic tumor even in the setting of unresectable but limited hepatic metastases may be indicated.
AB - Background: Pancreatic nonfunctioning neuroendocrine tumors (PNFNETs) are an uncommon malignancy and often present with metastatic disease. There is a lack of information on the management of the primary tumor in patients who present with unresectable synchronous hepatic metastases. Methods: A retrospective review (2001-2008) of PNFNETs was conducted. Patients were divided into 3 groups: PNFNET without evidence of hepatic metastasis (group A), PNFNET with metastatic disease involving less than 50% of the liver (group B), and PNFNET with metastatic disease involving more than 50% of the liver (group C). Clinical data and outcomes were analyzed. Results: Thirty-five patients with PNFNET were identified (group A = 15, group B = 11, group C = 9). Resection of the pancreatic tumor was performed in 26 patients. With a mean follow-up period of 30 months, death from disease progression occurred in 1 patient in group A, none in group B, and in 7 in group C. Conclusions: In selected patients, resection of the primary pancreatic tumor even in the setting of unresectable but limited hepatic metastases may be indicated.
KW - Pancreatic endocrine tumors
KW - Pancreatic neoplasm
KW - Pancreatic surgery
UR - http://www.scopus.com/inward/record.url?scp=60549095160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60549095160&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2008.11.005
DO - 10.1016/j.amjsurg.2008.11.005
M3 - Article
C2 - 19245918
AN - SCOPUS:60549095160
SN - 0002-9610
VL - 197
SP - 376
EP - 381
JO - American journal of surgery
JF - American journal of surgery
IS - 3
ER -